3 results
Search Results
Now showing 1 - 3 of 3
Publication Open Access Radiation Dosimetry in Non-Hodgkin’s B-Cell Lymphoma Patients Treated with 131I-Rituximab Radioimmunotherapy(2017) Wirote Changmuang; Arpakorn Kositwattanarerk; Kittipong Thongklam; Kanokon Poonak; Putthiporn Charoenphun; Thanete Doungta; วิโรจน์ ช่างม่วง; อาภากร โฆษิตวัฒนฤกษ์; กิตติพงษ์ ทองกล่ำ; กนกอร ภู่นาค; พุทธิพรณ์ เจริญพันธุ์; ธเนศ ดวงตา; Mahidol University. Faculty of Medicine Ramathibodi Hospital. Department of Diagnostic and Therapeutic Radiology; Thailand Institiute of Nuclear Technology (Public Organization). Radioisotope Center. Conclusions: The whole body radiation dose using a patient-specific tracer dose calculation based on whole body absorbed dose of 0.75 Gy was appropriate for therapeutic dose calculation in Radioimmunotherapy (RIT) patient.Publication Metadata only 131I-rituximab treatment in patient with relapsed non-Hodgkin's lymphoma: The first case report in Thailand(2013-06-13) Arpakorn Kositwattanarerk; Wirote Changmuang; Jatupol Sangsuriyan; Kittiphong Thongklam; Chanika Sritara; Chirawat Utamakul; Wichana Chamroonrat; Kanungnij Thamnirat; Yoch Anongpornyochkul; Suporn Chancharunee; Mahidol University; Thailand Institute of Nuclear Technology (Public Organization)Radioimmunotherapy (RIT) with131I-rituximab is a safe and effective treatment in patients with relapsed, refractory follicular lymphoma. The authors demonstrated the first case of131I-rituximab treatment in the patient with relapsed non-HodgkinPublication Open Access Radiotherapy as an Immunosuppressive Agent for Allotransplantation: Literature Review and Clinical Experience - Past, Present, and Future(2018) Chuleeporn Jiarpinitnun; Thiti Swangsilpa; Puangpen Tangboonduangjit; Rasin Worawongsakul; Orawan Rattanasuwan; ชุลีพร เจียรพินิจนันท์; ธิติ สว่างศิลป์; พวงเพ็ญ ตั้งบุญดวงจิตร; ราศิน วรวงศากุล; อรวรรณ รัตนสุวรรณ; Mahidol University. Faculty of Medicine Ramathibodi Hospital. Department of RadiologyRadiotherapy could function as immunosuppressive agent for allotransplantation due to the ability of ionizing radiation to cause cell death, the technique could be applied to irradiate total body, bone marrow and/or lymphoid tissues of the recipient who receive an allograft as an immunosuppressant to improve the success rate of transplantation. From the past to the present, the radiation techniques in allotransplantation process have been continuously studied and developed across preclinical and clinical settings, in order to achieve better therapeutic outcomes. Currently, total lymphoid irradiation by fractionation and total body irradiation with low dose are most frequently used radiotherapy techniques in allotransplantation process. The advanced radiotherapy techniques such as total marrow and/or lymphoid irradiation by volumetric arc therapy (VMAT) or helical tomotherapy (HT) have gained interests. These advanced techniques could increase therapeutic ratio by improving conformity high radiation dose to the targets and reducing dose to the surrounding normal tissues. This review aims to provide the insights of radiotherapy applications as an immunosuppressive agent for allotransplantation and to share clinical experiences and outcomes.